BMS expands PeptiDream macrocyclic peptide alliance
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has further extended its macrocyclic peptide drug discovery alliance with PeptiDream, providing further Big Pharma validation of the Japanese bioventure's technology and capabilities.